Shopping Cart

Your shopping cart is currently empty

Scutellarin

Name: Scutellarin
Brand: TargetMol
SKU: T2789
Price: 30 USD
Availability: InStock
Rating: 5 (10 reviews)

(Synonyms: Scutellarein-7-glucuronide, Breviscapinun, Breviscapine, Breviscapin) Copy Product Info

😃Good

Synonyms: Scutellarein-7-glucuronide, Breviscapinun, Breviscapine, Breviscapin

Catalog No. T2789 Copy Product Info

Purity: 99.75%

😃Good

Scutellarin (Breviscapin) is a natural flavonoid isolated from Scutellaria baicalensis that exhibits antioxidant, anti-inflammatory, antithrombotic, neuroprotective, and cardioprotective and neuroprotective activities. Scutellarin demonstrates antiviral activity against HIV-1 IIIB, HIV-1 (74V), and HIV-1 KM018. Scutellarin inhibits the RANKL-mediated MAPK/NF-κB pathway (IC₅₀ = 10 μM) and activates the Nrf2/HO-1 antioxidant pathway (EC₅₀ = 5 μM). Scutellarin can be used in natural product development and basic research on cardiovascular and cerebrovascular diseases.

Cas No. 27740-01-8

Pack Size	Price	USA Stock	Global Stock
5 mg	$30	In Stock	In Stock
10 mg	$41	In Stock	In Stock
25 mg	$68	In Stock	In Stock
50 mg	$121	In Stock	In Stock
100 mg	$155	In Stock	In Stock
500 mg	$377	In Stock	In Stock
1 mL x 10 mM (in DMSO)	$30	In Stock	In Stock

For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Cart

Add to Quotation

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Select Batch

Purity:99.75%

Color:White to Yellow

Resource Download

COA HNMR LCMS

Product Introduction

Bioactivity

Description	Scutellarin (Breviscapin) is a natural flavonoid isolated from Scutellaria baicalensis that exhibits antioxidant, anti-inflammatory, antithrombotic, neuroprotective, and cardioprotective and neuroprotective activities. Scutellarin demonstrates antiviral activity against HIV-1 IIIB, HIV-1 (74V), and HIV-1 KM018. Scutellarin inhibits the RANKL-mediated MAPK/NF-κB pathway (IC₅₀ = 10 μM) and activates the Nrf2/HO-1 antioxidant pathway (EC₅₀ = 5 μM). Scutellarin can be used in natural product development and basic research on cardiovascular and cerebrovascular diseases.
Targets & IC50	CYP1A2:95.2 µM (Ki), Rosuvastatin uptake (mediated via hOATP1B3):45.54 ± 6.67 μM, K562 cells viability:6 μM, 4-acetamidophenol:108.20 ± 0.657 µM, Rosuvastatin uptake (mediated via rOATP1B2):27.58 ± 3.97 μM
In vitro	Methods: Different concentrations of Scutellarin (0 μg/mL, 23.14 μg/mL, 42.68 μg/mL, 92.56 μg/mL) were added to SF-295 cells and incubated for 48 hours. Apoptosis was detected using flow cytometry. Results: Scutellarin significantly induced apoptosis in a dose-dependent manner, with the apoptosis rate increasing with concentration. [1] Methods: In rat primary liver cells, hepatocytes were co-incubated with RSV (20 μM) and different concentrations of Scutellarin (20, 50, 100 μM) at 37°C for 40 seconds. Intracellular RSV accumulation was detected using LC-MS/MS. Results: Scutellarin inhibited RSV uptake in a concentration-dependent manner: 20 μM inhibited uptake by 4.71%, 50 μM by 22.73%, and 100 μM by 45.89%.[2]
In vivo	Methods: Rats were injected with 10 μL of U251 cell suspension (1 × 10⁷ cells/mL) to induce an orthotopic tumor model. They were divided into a DMSO negative control group, a temozolomide positive control group, a low-dose scutellarin treatment group (20 mg/kg), and a high-dose scutellarin treatment group (50 mg/kg). administered intraperitoneally once daily. Results: Scutellarin administration improved animal survival rates. [1]
Synonyms	Scutellarein-7-glucuronide, Breviscapinun, Breviscapine, Breviscapin
Cell Research	HepG2 cells (1×105/well) are cultured in 96-well plates and treated in triplicate with scutellarin at concentrations of 5, 10, 20, 30, and 100 μM or vehicle alone for 24 h. The cellular viability is tested by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, and is expressed as a percentage of proliferation versus controls.

Chemical Properties

Molecular Weight	462.36
Formula	C₂₁H₁₈O₁₂
Cas No.	27740-01-8
Smiles	O[C@H]1[C@H](Oc2cc3oc(cc(=O)c3c(O)c2O)-c2ccc(O)cc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O
Relative Density.	1.81 g/cm3

Storage & Solubility Information

Storage

Keep away from direct sunlight Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 240 mg/mL (519.08 mM), Sonication is recommended.

H2O: insoluble

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.1628 mL	10.8141 mL	21.6282 mL	108.1408 mL
5 mM	0.4326 mL	2.1628 mL	4.3256 mL	21.6282 mL
10 mM	0.2163 mL	1.0814 mL	2.1628 mL	10.8141 mL
20 mM	0.1081 mL	0.5407 mL	1.0814 mL	5.4070 mL
50 mM	0.0433 mL	0.2163 mL	0.4326 mL	2.1628 mL
100 mM	0.0216 mL	0.1081 mL	0.2163 mL	1.0814 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.